Drug Profile
Donafenib - Suzhou Zelgen Biopharmaceuticals
Alternative Names: CM 4307; Donafenib tosilate; Donafenib tosylate; Zeprosen®; ZeprosynLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Developer Peking Union Medical College Hospital; Suzhou Zelgen Biopharmaceuticals
- Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Fluorinated hydrocarbons; Organic deuterium compounds; Phenyl ethers; Pyridines; Small molecules
- Mechanism of Action Platelet-derived growth factor receptor antagonists; Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Liver cancer
- Phase III Colorectal cancer; Thyroid cancer
- Phase II Biliary cancer; Cervical cancer
- Phase I/II Gastric cancer; Gastrointestinal cancer; Nasopharyngeal cancer; Oesophageal cancer; Solid tumours
- No development reported Acute myeloid leukaemia; Non-small cell lung cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Prevention of relapse, Adjuvant therapy) in China (PO, Tablet)
- 07 Jul 2023 Efficacy and adverse events data from a phase I trial in Liver cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 13 Jun 2023 Suzhou Zelgen Biopharmaceuticals terminates a phase I/II trial in Oesophageal cancer (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Monotherapy) in China, due to corporate policy adjustments (PO, Tablet) (NCT02489201)